Sign in
Not yet taking people in NetherlandsPhase 1

Tests PACAB-002 in adults with ovarian cancer that has spread in the abdomen

Tests PACAB-002 for safety and dosing in adults with ovarian cancer spread to the abdomen.

Key facts

Who runs it
Nadeno Nanoscience AS
Where
Rotterdam, NetherlandsSee the site
Registry title
An open-label phase 1 dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and exploratory assessments of PACAB-002 in patients with ovarian cancer with peritoneal spread
Status
Not yet recruiting
Phase
Phase 1
People taking part
21 people, planned
Starts
1 Jan 2027
Expected to end
31 Dec 2028
Type of study
Interventional
Record updated
16 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult women with ovarian cancer that has spread within the abdomen (peritoneal spread). It tests the safety of PACAB-002 at rising doses.

Age
18 years or older
Sex
Women only
Disease stage
Ovarian cancer with peritoneal spread

Where in Netherlands

  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests PACAB-002 in adults with ovarian cancer that has spread in the abdomenGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
16 October 2026